Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

191.18 -2.63 (-1.36%)

Streaming Delayed Price Updated: 12:06 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

47 48 Next >

Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗

August 28, 2025

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.

Via Benzinga

Reflecting On Therapeutics Stocks’ Q2 Earnings: Moderna (NASDAQ:MRNA)

August 27, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Moderna...

Via StockStory

Topics Artificial Intelligence

UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression ↗

August 27, 2025

Via Stocktwits

1 S&P 500 Stock on Our Watchlist and 2 Facing Headwinds

August 27, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Analyst Expectations For Biogen's Future ↗

August 14, 2025

Via Benzinga

Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday? ↗

July 31, 2025

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.

Via Benzinga

Topics Economy

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Biogen's Earnings Outlook ↗

July 30, 2025

Via Benzinga

S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot ↗

August 26, 2025

The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon.

Via Benzinga

Topics Stocks

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs ↗

August 22, 2025

Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs...

Via Benzinga

Topics Government World Trade

2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore

August 20, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

August 19, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.

Via StockStory

Topics Artificial Intelligence

Wondering what's happening in today's S&P500 pre-market session? ↗

August 18, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

August 14, 2025

Via Benzinga

Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks

August 13, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.

Via StockStory

Topics Artificial Intelligence

Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment ↗

August 13, 2025

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly.

Via Benzinga

Exploring the top movers within the S&P500 index during today's session. ↗

August 13, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance

August 12, 2025

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above...

Via StockStory

Beyond The Numbers: 8 Analysts Discuss Biogen Stock ↗

August 01, 2025

Via Benzinga

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate ↗

July 31, 2025

Biogen beat Q2 earnings and revenue estimates, raised full-year EPS guidance, and posted strong gains in Alzheimer's and rare disease drugs.

Via Benzinga

Biogen (NASDAQ:BIIB) Reports Bullish Q2

July 31, 2025

Via StockStory

Topics Artificial Intelligence

Biogen Earnings: What To Look For From BIIB

July 29, 2025

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

1 Nasdaq 100 Stock to Target This Week and 2 That Underwhelm

July 25, 2025

While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that...

Via StockStory

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division ↗

July 22, 2025

George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and drug advertising rules.

Via Benzinga

Biogen (BIIB) Stock Trades Down, Here Is Why

July 21, 2025

Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist downgraded the stock, citing concerns over the company's growth prospects and high-risk...

Via StockStory

Topics Lawsuit

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing ↗

July 21, 2025

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage clinical pipeline support.

Via Benzinga

What's going on in today's session: S&P500 movers ↗

July 21, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know

July 18, 2025

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...

Via StockStory

Topics Lawsuit

< Previous 1 2 3 4 5 6 7 8 9

...

47 48 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.